Prostate tumor delineation using multiparametric magnetic resonance imaging: Inter-observer variability and pathology validation - Abstract

BACKGROUND AND PURPOSE: Boosting the dose to the largest (dominant) lesion in radiotherapy of prostate cancer may improve treatment outcome.

The success of this approach relies on the detection and delineation of tumors. The agreement among teams of radiation oncologists and radiologists delineating lesions on multiparametric magnetic resonance imaging (mp-MRI) was assessed by measuring the distances between observer contours. The accuracy of detection and delineation was determined using whole-mount histopathology specimens as reference.

MATERIAL AND METHODS: Six observer teams delineated tumors on mp-MRI of 20 prostate cancer patients who underwent a prostatectomy. To assess the inter-observer agreement, the inter-observer standard deviation (SD) of the contours was calculated for tumor sites which were identified by all teams.

RESULTS: Eighteen of 89 lesions were identified by all teams, all were dominant lesions. The median histological volume of these was 2.4cm3. The median inter-observer SD of the delineations was 0.23cm. Sixty-six of 69 satellites were missed by all teams.

CONCLUSION: Since all teams identify most dominant lesions, dose escalation to the dominant lesion is feasible. Sufficient dose to the whole prostate may need to be maintained to prevent under treatment of smaller lesions and undetected parts of larger lesions.

Written by:
Steenbergen P, Haustermans K, Lerut E, Oyen R, De Wever L, Van den Bergh L, Kerkmeijer LG, Pameijer FA, Veldhuis WB, van der Voort van Zyp JR, Pos FJ, Heijmink SW, Kalisvaart R, Teertstra HJ, Dinh CV, Ghobadi G, van der Heide UA.   Are you the author?
Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Radiation Oncology, University Hospitals Leuven, Department of Oncology, KU Leuven, Belgium; Pathology, University Hospitals Leuven, Department of Imaging & Pathology, KU Leuven, Belgium; Radiology, University Hospitals Leuven, Department of Imaging & Pathology, KU Leuven, Belgium; Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands; Department of Radiology, University Medical Center Utrecht, The Netherlands; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.  

Reference: Radiother Oncol. 2015 May;115(2):186-90.
doi: 10.1016/j.radonc.2015.04.012


PubMed Abstract
PMID: 25935742

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe